Bernie Gets Mostly Pharma-Friendly Drug Pricing Results

 
• By Sarah Karlin-Smith

Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.

Sen. Bernier Sanders speakers at a press conference. Sen. Tammy Baldwin and Ben Ray Lujan appear behind him.
Sen. Bernie Sanders led a press conference on inhaler price changes 22 March. • Source: Office of Bernie Sanders

More from Pricing Debate

More from Market Access